Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent - Test2 - elhamkhani - TriplyDB

Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent

Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent

http://www.wikidata.org/entity/Q28475431

about

Drug resistance analysis by next generation sequencing in Leishmania Single dose novel Salmonella vaccine enhances resistance against visceralizing L. major and L. donovani infection in susceptible BALB/c mice Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective Advances in Development of New Treatment for Leishmaniasis Health economic evaluations of visceral leishmaniasis treatments: a systematic review Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis A poor-quality generic drug for the treatment of visceral leishmaniasis: a case report and appeal Leishmania donovani develops resistance to drug combinations Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India Antimony transport mechanisms in resistant leishmania parasites.Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.Vector saliva in vaccines for visceral leishmaniasis: a brief encounter of high consequence?Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects.Developments in diagnosis and treatment of visceral leishmaniasis during the last decade and future prospects.The household costs of visceral leishmaniasis care in south-eastern Nepal.Systematic literature review to evaluate and characterize the health economics and outcomes research studies in India.Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh Molecular factors governing inhibition of arylimidamides against Leishmania: conservative computational modeling to improve chemotherapies.New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas.Novel Agents against Miltefosine-Unresponsive Leishmania donovani.Short-Course Treatment Regimen of Indian Visceral Leishmaniasis with an Indian Liposomal Amphotericin B Preparation (Fungisome™).Liposomal amphotericin B as a treatment for human leishmaniasis Synthesis and structure-activity relationships of lansine analogues as antileishmanial agents.The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis Introducing single dose liposomal amphotericin B for the treatment of visceral leishmaniasis in rural bangladesh: feasibility and acceptance to patients and health staff.Socio-economic aspects of neglected diseases: sleeping sickness and visceral leishmaniasis.Leishmaniasis: new insights from an old and neglected disease.Efficacy of a Binuclear Cyclopalladated Compound Therapy for Cutaneous Leishmaniasis in the Murine Model of Infection with Leishmania amazonensis and Its Inhibitory Effect on Topoisomerase 1B.A Systematic Review of the State of Economic Evaluation for Health Care in India.A Mathematical Study to Control Visceral Leishmaniasis: An Application to South Sudan.Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar).Nanostructured delivery systems with improved leishmanicidal activity: a critical review.Study of implementation and direct cost estimates for diagnostic tests for human visceral leishmaniasis in an urban area in Brazil.Towards elimination of visceral leishmaniasis in the Indian subcontinent-Translating research to practice to public health.Augmentation of antileishmanial efficacy of miltefosine in combination with tuftsin against experimental visceral leishmaniasis.Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.Leishmaniasis in humans: drug or vaccine therapy?Synthesis and Evaluation of Methyl 4-(7-Hydroxy-4,4,8-Trimethyl-3-Oxabicyclo[3.3.1]Nonan-2-yl)Benzoate as an Antileishmanial Agent and Its Synergistic Effect with Miltefosine.Cost-effectiveness analysis of thermotherapy versus pentavalent antimonials for the treatment of cutaneous leishmaniasis.Poly(methacrylic acid) complexation of amphotericin B to treat neglected diseases

P2860

Q26851222-9C10582A-154F-4A63-95C5-BBCE2E715A1F Q27305906-6F074BAA-7AC7-4475-89DA-616363AB0E14 Q28073426-150BFFDD-FB20-4D94-9FE2-8D88CC801167 Q28082097-C11A4743-2B62-4D00-B0E7-C3639E422D53 Q28084540-32742958-E583-467E-9006-D86307418433 Q28271849-0FB3C84E-940B-45F4-BBCF-27E5688065B2 Q28483975-FD672CD3-C65B-4B05-A7AC-EE68B5D01760 Q28484463-05817A88-7EC2-46E4-B2DF-0F0B24E5A5FE Q28538265-8BBA0530-867D-4B1E-AAC8-CF1D5CAB908D Q33659312-4DD589D3-8037-4D8F-AD0F-DF3AA897BB01 Q33783806-A67C66BB-77C8-4199-AC19-FC986EA97B9E Q34019064-12F41D19-1FFD-414F-BA1C-28254978A379 Q34054948-823CA1A6-CAC0-4C2A-91B6-468A8136E4CE Q34328882-BF633A68-6DA9-4F2A-93E1-51A528F38A9A Q34613587-3C81E143-0C19-4FF4-A73B-1D583A93055E Q35041601-F369F822-B4E8-4690-9D54-8A9F27C7E8C5 Q35065586-5A65E950-4413-41FA-A015-B4E0325BFF66 Q35189818-E46336EC-00DE-4808-B45C-BC7E34878774 Q35219247-28CFD47C-C9D4-46E7-8CD8-989A1291C088 Q36290836-F9568517-7549-4E17-A527-4F37CCADCD3F Q36455848-F9E1B6A6-16BB-46E9-8464-F5E5B4B00EAF Q36456032-55D25CE2-A5D2-4D5B-A0AA-A36D2DBE6C11 Q36589075-D13BBEB2-1878-47DA-B25A-94C7C5D14BEA Q36932080-A8A32C5E-793C-40FB-BA55-9332944F3A0B Q37569747-46A3D7CD-1877-4CE4-BB2C-4CE1E73F9701 Q37811110-61C9EBCD-4FA9-48A4-BA67-FDAC5150CC8C Q37870821-0811C062-175C-4BFC-AAF9-7CE7594C12B8 Q38376759-0C1C74C4-E33D-4B2B-B6E5-8B6E499B8C31 Q38602629-55121F20-7CE4-484D-8AE7-C49F458904CA Q38867806-D9AAD3BA-D65D-458B-9F9D-64BD737E57FA Q39599468-4FD0DEBE-027E-474C-853B-AA404A8085D0 Q40099567-C950D0D4-60D4-40F3-9A55-D4C0D4ADA08B Q40342021-AB5BEA6B-FE70-4119-9311-32E9B6479AE8 Q43167558-EB17859D-A588-4F42-84BC-38874D117E40 Q43561343-E42CC5BB-CD21-430C-9ED3-F8F9B1F82732 Q45363637-FC69C2ED-3A04-4763-A6CD-B78F909F3C1C Q47556262-820A9AF4-ABCD-4FC3-9758-415B81135682 Q50042596-7EFF66AA-D26B-47C9-B772-3A080474847A Q50677795-F0CDAC9F-E4E9-4E1A-8CE5-92E4799E1B63 Q57347954-87CF1E47-1B7D-4F00-ADCC-10E0D62E7A75

P2860

Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent

http://www.wikidata.org/entity/Q28475431

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Cost-effectiveness analysis of ...... sis in the Indian subcontinent

@ast

Cost-effectiveness analysis of ...... sis in the Indian subcontinent

@en

Cost-effectiveness analysis of ...... sis in the Indian subcontinent

@nl

type

label

Cost-effectiveness analysis of ...... sis in the Indian subcontinent

@ast

Cost-effectiveness analysis of ...... sis in the Indian subcontinent

@en

Cost-effectiveness analysis of ...... sis in the Indian subcontinent

@nl

prefLabel

Cost-effectiveness analysis of ...... sis in the Indian subcontinent

@ast

Cost-effectiveness analysis of ...... sis in the Indian subcontinent

@en

Cost-effectiveness analysis of ...... sis in the Indian subcontinent

@nl

P1433

Q28475431-E7E3065E-4A7F-4372-868D-D6521FA7550A

P1476

Q28475431-F03C77AC-5803-4916-82FB-B2A9FE2908C5

P2093

Q28475431-1411696D-342D-4E1C-9905-1BBEC96C4DDA

Q28475431-BC52E69A-1E30-4C0E-AE9D-03D7ADB86375

Q28475431-F40AE34D-1822-47BC-9D9E-11CAA42380C7

Q28475431-F77D2803-77F7-443F-884E-91600C3525A0

P275

Q28475431-F9B5FF9E-058A-4C7C-90B7-384F78AA44FC

P2860

Q28475431-1A1E5548-70C1-42C4-9DFE-2B017C1C724B

Q28475431-1AEEF51A-EB4E-409D-8AB8-65C5072D7EE4

Q28475431-23DC6C79-D81A-4E68-AF75-5AC0FFE3C509

Q28475431-37EF1CB4-5EF5-4A36-AFE0-996843EA24BF

Q28475431-37F3089F-8532-46D3-9259-F580E5AAE3ED

Q28475431-49E4166E-B349-442F-8664-0F2020720A21

Q28475431-49E5B46C-F383-4F86-AF23-74221D4D9E16

Q28475431-4CACC3F9-E144-47E4-BFA7-C5DAD001E1AC

Q28475431-4E31C983-F928-40C5-A255-EDCDF1E6ED9A

Q28475431-5277447E-9C69-4BD0-B0CA-EF978411707F

P304

Q28475431-478EB97C-774A-4125-AEFC-D8622B6A418B

P31

Q28475431-3CADD14D-51A7-489B-9D36-8F38508090CC

Q28475431-ea7cb5f9-45d8-2d96-4097-8fa8709e6e1b

P3181

Q28475431-4E659A08-5979-44D3-86CF-4F5D07959745

P356

Q28475431-DD43835D-F889-4E89-B997-E899DAD5FD65

P407

Q28475431-DBCFF5A0-B492-4940-A545-87A0A8773C68

P433

Q28475431-41F2EE3F-F2D9-464A-97D8-A9279DA4A261

P478

Q28475431-96DC4E86-CC6D-404F-BBDF-32CEAA670056

P50

Q28475431-AF1709FA-78B5-45DF-ACD3-76189E2B81CB

Q28475431-B8D1BC80-9903-4DAE-A7A7-296D86E8C524

Q28475431-FCA29369-2BCE-454E-B268-02B7122390B2

P5008

Q28475431-D9CBF494-9DE3-4098-970E-8910E229BB24

P577

Q28475431-A9B1D107-7C41-4505-8333-00E3A7894CB5

P5875

Q28475431-C8ACD558-85B8-4BCB-BACD-F103A839CE9D

P698

Q28475431-3AE4958E-BA98-428F-AB37-319F2A745B54

P921

Q28475431-3D23A072-0AFC-4C76-9569-48B970100095

Q28475431-82E834EF-F26F-4F50-9B8D-2608A9D73041

Q28475431-CA0D588B-37B5-4ADE-B5B4-7FAC5D0135FF

P932

Q28475431-B637C099-AE8C-4CD1-B4B4-7FAFA98567BA

P3181

P356

JOURNAL.PNTD.0000818

P1433

PLOS Neglected Tropical Diseases

P1476

Cost-effectiveness analysis of ...... sis in the Indian subcontinent

@en

P2093

Filip Meheus

http://www.w3.org/2001/XMLSchema#string

Manica Balasegaram

http://www.w3.org/2001/XMLSchema#string

Md Abul Faiz

http://www.w3.org/2001/XMLSchema#string

Suman Rijal

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases

Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India

Single-dose liposomal amphotericin B for visceral leishmaniasis in India

Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial

Epidemiology of visceral leishmaniasis in India.

Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.

Oral miltefosine for Indian visceral leishmaniasis.

Injectable paromomycin for Visceral leishmaniasis in India.

Liposomal amphotericin B for the treatment of visceral leishmaniasis.

P304

e818

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

cost–benefit analysis

P3181

1413524

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PNTD.0000818

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Marleen Boelaert

P5008

P577

2010-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46256575

http://www.w3.org/2001/XMLSchema#string

P698

20838649

http://www.w3.org/2001/XMLSchema#string

P921

infectious disease

visceral leishmaniasis

P932

2935395

http://www.w3.org/2001/XMLSchema#string